Genocea Biosciences
Priced, Nasdaq: GNCADevelops novel vaccines for infectious diseases through T cell immune responses.
Industry: Health Care
First Day Return: -8.3%
GNCA
Develops novel vaccines for infectious diseases through T cell immune responses.
| IPO Date | 02/04/2014 |
|---|---|
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $66 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| IPO Intelligence Only |
| Headquarters | Cambridge, MA, United States |
|---|---|
| Founded | 2006 |
| Employees at IPO | 39 |
| Website www.genocea.com | |
IPO News for Genocea Biosciences
Genocea Biosciences (GNCA) Performance
